Methods for evaluating tissue morphogenesis and activity
US7147839B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 29, 1998 |
| Grant date | Dec 12, 2006 |
| Priority date | — |
| Expiry date | May 29, 2018 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.) It further has been discovered that a single injection of morphogenic protein is sufficient to induce the desired biological effect, and that administration is not time-sensitive, provided mesenchymal progenitor cells are accessible to the defect site. That is, morphogenic protein can be provided to an individual having a local permissive defect site, shortly after creation of the d…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.